Oracle Corp. is buying Irvine’s Relsys International Inc., a maker of software for drug makers.
Terms of the deal weren’t disclosed. The acquisition is set to close in the second quarter.
Relsys makes software that helps drug makers comply with regulations as they test potential drugs in clinical trials. Its software also helps drug makers manage safety data for their products.
Customers include Irvine’s Allergan Inc., Switzerland’s Novartis AG and Denmark’s Novo Nordisk AS.
Oracle is buying Relsys as part of an effort to build its business selling software to drug makers and other healthcare companies.
Relsys is set to become part of Oracle’s health sciences business unit.
The company was started in 1987. Founder Dave Bajaj runs Relsys as chief executive.
